bioRxivSynthetic BiologyPreprint
DNA-templated spatially controlled proteolysis targeting chimeras for CyclinD1-CDK4/6 complex protein degradation
Rong Zheng, Abhay PrasadiD, Deeksha SatyabolaiD, Yang XuiD, Hao YaniD
Abstract
Constraining proximity-based drugs, such as proteolysis-targeting chimeras (PROTACs), into its bioactive conformation can significantly impact their selectivity and potency. However, traditional methods for achieving this often involve complex and time-consuming synthetic procedures. Here, we introduced an alternative approach by demonstrating DNA-templated spatially controlled PROTACs (DTACs), which leverage the programmability of nucleic-acid based self-assembly for efficient synthesis, providing precise control over inhibitors spacing and orientation. The resulting constructs revealed distance- and orientation-dependent selectivity and degradation potency for the CyclinD1-CDK4/6 protein complex in cancer cells. Notably, an optimal construct DTAC-V1 demonstrated the unprecedented synchronous degradation of entire CyclinD1-CDK4/6 complex. This resulted in the effective cell cycle arrest in G1 phase, and further therapeutic studies showed its potent anti-tumor effects compared to inhibitors alone. These findings present a novel framework for PROTACs design, offering critical insights that may inform the development of other proximity-induced therapeutic modalities.
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cooperatively Designed Aptamer-PROTACs for Spatioselective Degradation of Nucleocytoplasmic Shuttling Protein for Enhanced Combinational Therapy
- Chimeric Collagen-like Proteins with Tunable Structural Heterogeneity for Precise Control and Targeted Doxorubicin Delivery
Yan Xia, Yimiao Li, … Xinyu Li·Journal of Controlled ReleasePeer-reviewed·Aug 15, 2025
- PSMA-Guided PROTAC Degraders for Tumor-Specific Protein Degradation in Prostate Cancer
Xiao-Lei Meng, Xiaolin Hu, … Chong Qin·Journal of Medicinal ChemistryPeer-reviewed·May 2, 2025
- Beyond Dmax and DC50: A simple tool to evaluate the complex PROTAC-mediated kinetic degradation dynamics
Smitha Kizhake, Amarnath Natararajan·bioRxiv·Sep 22, 2026
- Target engagement studies and kinetic live-cell degradation assays enable the systematic characterization of HDAC6 PROTACs
Maria Hanl, Felix Feller, … Finn Kristian Hansen·bioRxiv·Mar 31, 2025
- Predicting PROTAC-targeted Degradation and Designing Androgen Receptor Degraders with AiPROTAC
Li Zhang, Renhong Sun, … Xing Chen·bioRxiv·Feb 26, 2025